Shares of Harrow Health cratered 9.1% to $36.98 after the eye-drug specialist posted second-quarter results Monday evening that deepened the market's concerns about profitability even as its flagship dry-eye treatment gains traction. The company reported a net loss of $17.3 million, or $0.46 per share , on quarterly revenue of $70.7 million, an increase of 60% sequentially and 11% year over year . The headline numbers fell short on both counts: Wall Street expected a loss of just $0.23 per share , and revenue also missed forecasts of $71.1 million .

  • The Loss Was Twice as Bad as Expected — At $0.46, the per-share loss was double the consensus estimate, meaning the company burned cash far faster than analysts modeled. This marks the second consecutive miss; in Q1, Harrow lost $0.74 per share versus estimates of $0.43, on revenue of just $44.2 million . Two straight quarters of widening losses erode confidence in management's ability to turn sales growth into actual profit.

  • VEVYE Is Growing, but Not Paying for Itself Yet — The company's dry-eye drug reached 805 total ordering accounts, adding 69 new accounts in the quarter, with May 2026 marking its strongest-ever month — up 151% versus May 2025 . Effective August 1, the drug also gained expanded coverage with a top-three national pharmacy benefits manager . Yet heavy sales-force spending and insurance-related pricing adjustments are eating into returns. Demand is real; margin is not — yet.

  • Guidance Held Firm, Which May Be the Biggest Risk — Harrow reaffirmed full-year revenue guidance of $350–$365 million . With first-half revenue totaling roughly $115 million, the company needs approximately $240 million in the second half — more than double the first half. That bar got "meaningfully larger" after Q1, and it depends on clean execution across every second-half catalyst, from new product launches to pricing recovery . Maintaining guidance after consecutive misses can look like confidence or denial; the market is leaning toward the latter.

  • A Credibility Problem Is Building — Harrow sits 34% below its 52-week high of $54.85, with a market cap of roughly $1.4 billion and a debt-to-equity ratio of 10.3 — extremely high leverage for a company still losing money. Cantor Fitzgerald recently cut its price target from $91 to $88 , and further downgrades look likely after this report. Until losses narrow, the stock will keep trading on skepticism rather than on the promise of its drug portfolio.